SGH
OREX

Sivik Global Healthcare’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Sivik Global Healthcare’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-12,415
Closed -$807K – 85
2014
Q1 		$807K Buy
+12,415
New +$840K 0.5% 63

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sivik Global Healthcare's OREX Position: Q2 2014 in Review

Sivik Global Healthcare sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2014, closing a stake of 12,415 shares — an estimated $807K sold.

Sivik Global Healthcare first reported a position in OREX in Q1 2014 and held it in 1 quarter. The position peaked at $807K in Q1 2014. 129 funds tracked by Wall St. Rank hold OREX as of Q2 2014.

  • Sivik Global Healthcare reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Sivik Global Healthcare sold 12,415 Orexigen Therapeutics, Inc. shares in Q2 2014, an estimated $807K.
  • Sivik Global Healthcare first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • Sivik Global Healthcare's Orexigen Therapeutics, Inc. position peaked at $807K in Q1 2014.
  • 129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2014.

Based on Sivik Global Healthcare's 13F filing for Q2 2014, filed 3 Jul 2014.